Avalon GloboCare Corp. (NASDAQ:CHGA) Sees Significant Decline in Short Interest

Avalon GloboCare Corp. (NASDAQ:CHGA) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 68,808 shares, a drop of 69.7% from the August 15th total of 226,852 shares. Based on an average daily volume of 723,976 shares, the days-to-cover ratio is currently 0.1 days. Approximately 9.6% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, August 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Avalon GloboCare Price Performance

Shares of CHGA traded down $0.02 during mid-day trading on Friday, reaching $2.23. 21,781 shares of the company’s stock were exchanged, compared to its average volume of 409,124. The stock has a market capitalization of $2.12 million, a PE ratio of -0.16 and a beta of -0.05. Avalon GloboCare has a 52-week low of $2.15 and a 52-week high of $57.97. The business’s fifty day simple moving average is $4.76 and its 200-day simple moving average is $7.94.

Avalon GloboCare (NASDAQ:CHGA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($2.80) earnings per share for the quarter.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.